Drug Trial Radar · NCT07215910
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Jun 24, 2026
Primary completion
May 31, 2033
Study completion Jan 2040
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.
Conditions
- Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation TherapyRadiation
Undergo IMRT/VMAT
Volume Modulated Arc TherapyRadiation
Undergo IMRT/VMAT
Pencil Beam ScanningRadiation
Undergo PBS
Intensity-Modulated Proton TherapyProcedure
Undergo IMPT
TemozolomideDrug
Given PO
VorasidenibDrug
Given PO
Placebo AdministrationDrug
Given PO
Biospecimen CollectionProcedure
Undergo blood sample collection
Magnetic Resonance ImagingProcedure
Undergo MRI
Questionnaire AdministrationOther
Ancillary Studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) by blinded independent central review (BICR)Time frame: assessed up to 10 years
Locations
177 sites in 1 country. Site status is shown where the registry gives one.
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Kaiser Permanente-Fresno
Fresno, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Kaiser Permanente-Ontario
Ontario, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Kaiser San Rafael-Gallinas
San Rafael, California · Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California · Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California · Recruiting
Kaiser Permanente-Vallejo
Vallejo, California · Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California · Recruiting
John Muir Medical Center-Walnut Creek
Walnut Creek, California · Recruiting
Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
Medical Center of the Rockies
Loveland, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida · Recruiting
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.